Immunovant, Inc. Form 10-Q Summary
Reporting period: Fiscal quarter and six months ended September 30, 2020. The company’s fiscal year ends March 31; therefore, this filing represents fiscal 2021 second-quarter results. Financial statements are unaudited and reflect the December 2019 reverse recapitalization.
Business Context
Immunovant is a clinical-stage biopharmaceutical company developing IMVT-1401, a fully human monoclonal antibody targeting the neonatal Fc receptor for IgG-mediated autoimmune diseases. The company has no approved products and has never generated product revenue. Clinical programs included myasthenia gravis, thyroid eye disease and warm autoimmune hemolytic anemia.
Key Financial Metrics
| Metric | Three Months Ended September 30, 2020 | Three Months Ended September 30, 2019 | Six Months Ended September 30, 2020 | Six Months Ended September 30, 2019 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $12.0 million | $10.3 million | $28.9 million | $28.8 million |
| General and administrative expense | $9.0 million | $4.2 million | $18.7 million | $5.7 million |
| Total operating expenses | $21.0 million | $14.5 million | $47.6 million | $34.6 million |
| Net loss | $20.8 million | $14.5 million | $47.5 million | $34.5 million |
| Net loss per share | $0.25 | $0.38 | $0.61 | $0.90 |
| Cash flow from operating activities | Not separately provided | Not separately provided | $(38.0) million | $(25.9) million |
Margins and profitability: Gross margin and operating margin are not meaningful because the company has no revenue. The company remains loss-making and expects significant additional losses.
Liquidity: Cash was $444.4 million at September 30, 2020, compared with $100.6 million at March 31, 2020. Total liabilities were $15.5 million, consisting primarily of accounts payable, accrued expenses and operating lease liabilities. The company had no significant debt outstanding at quarter-end.
Accumulated deficit: $138.7 million at September 30, 2020, compared with $91.2 million at March 31, 2020.
Material Changes Versus the Prior Comparable Period
- Quarterly net loss increased by $6.3 million, or approximately 44%, primarily due to higher operating expenses.
- Quarterly research and development expense increased by $1.7 million, driven mainly by expanded clinical and nonclinical studies and higher professional services costs.
- Quarterly general and administrative expense increased by $4.8 million, reflecting higher personnel costs, stock-based compensation, recruiting, commercial spending and rent.
- Six-month research and development expense was broadly flat year over year, but the prior-year period included a one-time $10.0 million HanAll development and regulatory milestone payment. Excluding that milestone, 2020 six-month research and development expense increased by approximately $10.1 million.
- Six-month general and administrative expense increased by $12.9 million, primarily from increased headcount, stock-based compensation, legal and professional fees and commercial spending.
- Cash increased substantially following equity financings and warrant exercises. The company raised approximately $131.0 million net in an April public offering, approximately $65.8 million from warrant exercises, and approximately $188.1 million net in a September public offering.
- Shares outstanding increased to 97,890,705 at September 30, 2020 from 54,655,376 outstanding at March 31, 2020. The company also issued 20.0 million earnout shares and vested 1.8 million sponsor restricted shares after achieving the applicable stock-price milestones.
Guidance, Outlook and Management Commentary
- Management expects to initiate a Phase 3 myasthenia gravis trial in the first half of calendar 2021.
- Initial results from the ASCEND GO-2 thyroid eye disease trial were expected in the first half of calendar 2021.
- Initial results from the high-dose cohort of the warm autoimmune hemolytic anemia Phase 2a trial were expected in the first quarter of calendar 2021.
- The company intended to announce three additional IMVT-1401 indications by August 2021.
- Based on cash at September 30, 2020 and current spending assumptions, management expected available cash to fund operating expenses and capital expenditures into the second half of calendar 2023. This estimate depends on assumptions that may prove inaccurate.
- Management expects research and development and general and administrative expenses to increase substantially as clinical programs advance, personnel are added and public-company requirements expand.
Risks, Contingencies and Unusual Items
- COVID-19 caused variable clinical-trial disruption, including temporary enrollment closures at some sites, and could affect enrollment, vendors, manufacturing, supply chains and timelines.
- IMVT-1401 is the company’s sole product candidate, making the business highly dependent on successful clinical development, regulatory approval and commercialization.
- The company will require additional capital to complete development and potential commercialization. It had no committed external source of funding, and future equity financing could dilute existing stockholders.
- Under the HanAll license agreement, the company may owe up to $442.5 million in development, regulatory and sales milestone payments, plus up to $20.0 million of shared research and development costs and tiered royalties ranging from the mid-single digits to mid-teens on net product sales.
- The company relies on third-party manufacturers, contract research organizations and clinical sites and has limited internal manufacturing and clinical-trial execution capabilities.
- Clinical results remain uncertain, and early reductions in IgG levels may not predict later-stage efficacy or safety outcomes. Regulatory approval has not been sought through a biologics license application.
- Roivant Sciences Ltd. controlled approximately 57.6% of voting power as of November 12, 2020, making Immunovant a controlled company under Nasdaq rules and creating potential conflicts with minority stockholders.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Disclosure controls and procedures were considered effective as of September 30, 2020.
Investor Verification Checklist
- Verify the timing, enrollment, endpoints and final results of the planned Phase 3 myasthenia gravis and other IMVT-1401 trials.
- Assess whether the projected cash runway to the second half of calendar 2023 remains credible after incorporating trial expansion, milestone payments, manufacturing costs and operating growth.
- Review the remaining contingent obligations, payment triggers and termination provisions under the HanAll Agreement.
- Monitor quarterly cash burn, stock-based compensation, equity issuance and dilution, including Roivant’s ownership and voting control.
- Evaluate the effect of COVID-19 and third-party manufacturing or clinical-site disruptions on development timelines and supply availability.
- Confirm whether preliminary clinical findings translate into statistically significant, clinically meaningful and regulatorily sufficient efficacy and safety results.